Drugs / NVC-422
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02130518 | Sep 2014 → Dec 2015 | urinary tract obstruction | NovaBay Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT01877694 | Jun 2013 → Dec 2014 | bacterial conjunctivitis | NovaBay Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01532336 | May 2012 → May 2014 | viral conjunctivitis | NovaBay Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01243125 | Nov 2010 → Jul 2013 | urinary tract obstruction | NovaBay Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01367314 | Aug 2009 → May 2010 | impetigo | NovaBay Pharmaceuticals, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-09-24 | Galderma R&D | Galderma and NovaBay Enroll First Patients in Phase 2b Clinical Study of NVC-422 for Impetigo galderma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVC-422 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01243125 ↗ |
| Known as | AIS | “Auriclosene (AIS)” NCT02130518 ↗ |
| Known as | Auriclosene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02130518 ↗ |
| Route | Other | “25 ml instilled and retained in catheter for 15 min, 2x/day” NCT01243125 ↗ |